



# Talk to your doctor. Get the most out of your next visit.

We understand the importance of talking to your doctor about your relapsing multiple sclerosis (MS) treatment. It's a decision that should not be taken lightly. Throughout your relapsing MS journey, your doctor is your partner, as well as your best resource for medical information. That's why it's important to keep the conversation open and clearly communicate your treatment goals.

To help you prepare for your next appointment, we suggest that you ask your doctor the following questions, in addition to any other questions you may have. These questions can help you have a productive conversation as you consider ZINBRYTA for treating your relapsing MS.

1. What is ZINBRYTA going to do for my relapsing MS and what are the risks?

---

---

---

2. ZINBRYTA is given by subcutaneous injection. What does that mean, and how often should I take it?

---

---

---

3. Will someone help me inject ZINBRYTA? Or, teach me how to do it?

---

---

---

## Indication

ZINBRYTA (daclizumab) is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, ZINBRYTA is generally used in people who have tried 2 or more MS medicines that have not worked well enough. It is not known if ZINBRYTA is safe and effective for use in children under 18 years of age.

## Selected Important Safety Information

**Because of the risk of serious liver problems and immune system problems, ZINBRYTA is only available through a restricted program called the ZINBRYTA Risk Evaluation and Mitigation Strategy (REMS) Program.**

For Important Safety Information, please see pages 3-4 and download the Full [Prescribing Information](#), including [Boxed Warning](#), and [Medication Guide](#) on ZINBRYTA.com.





4. What if I need financial assistance or cannot afford my medication?

---

---

---

5. How often should I visit you while I'm on ZINBRYTA?

---

---

---

6. What are some of the potential side effects of ZINBRYTA? Who should I call for advice on what to do if I experience side effects?

---

---

---

7. Why do we need to test my liver once a month and what will you do with the results? How and where will this be done?

---

---

---

8. Based on what we've discussed so far, do you think ZINBRYTA is right for me? If yes, how do I get started?

---

---

---

Remember that your doctor is always your primary resource for questions about your relapsing MS treatment. If you still have questions about the support and services available with ZINBRYTA, please call **1-800-456-2255** to speak with a member of our Patient Services team, who may be able to help.

**Selected Important Safety Information**

**Do not use ZINBRYTA if you:** have liver problems; have or have had autoimmune-related liver problems including autoimmune hepatitis; or are allergic to daclizumab or any of the other ingredients in ZINBRYTA.

For Important Safety Information, please see pages 3-4 and download the Full **Prescribing Information**, including **Boxed Warning**, and **Medication Guide** on ZINBRYTA.com.



**Zinbryta**<sup>®</sup>  
(daclizumab)

ONCE MONTHLY

150 mg Subcutaneous Injection



## Important Safety Information

**ZINBRYTA can cause serious side effects, including:**

**Liver problems**, including autoimmune-related liver problems that may lead to death. Your healthcare provider will do blood tests to check your liver before starting ZINBRYTA, every month while you are using ZINBRYTA, and monthly for 6 months after you stop using ZINBRYTA.

Call your healthcare provider right away if you have any of the following symptoms of liver problems: nausea or vomiting, stomach pain, unusual tiredness, not wanting to eat, yellowing of the skin or whites of your eyes, or dark urine.

**Immune system problems.** Some people using ZINBRYTA develop immune-mediated disorders, where the body's immune system attacks healthy cells in the body, and other immune system problems.


Call your healthcare provider right away if you have any of the following symptoms: skin reactions, such as rash or skin irritation; tender, painful, or swollen lymph nodes; symptoms of a low red blood cell count, which can include looking very pale, feeling more tired than usual, dark urine, shortness of breath, or yellowing of the skin or whites of your eyes; intestinal problems (colitis), symptoms of which can include fever, stomach pain, blood in your stools, or diarrhea that does not go away; or any new and unexplained symptoms in any part of your body.

**Because of the risk of serious liver problems and immune system problems, ZINBRYTA is only available through a restricted program called the ZINBRYTA Risk Evaluation and Mitigation Strategy (REMS) Program.**

**Do not use ZINBRYTA if you:** have liver problems; have or have had autoimmune-related liver problems including autoimmune hepatitis; or are allergic to daclizumab or any of the other ingredients in ZINBRYTA.

**Before using ZINBRYTA, tell your healthcare provider if you** have or have had: liver problems; skin problems, including eczema or psoriasis; tuberculosis or an active infection; are planning to receive a vaccine; have or have had depression; are pregnant or planning to become pregnant; are breastfeeding or planning to breastfeed. It is not known if ZINBRYTA will harm your unborn baby or if ZINBRYTA passes into your breast milk.

**Tell your health care provider about all the medicines, vitamins or supplements you take.** Using ZINBRYTA with certain medicines can cause serious side effects.

*ONCE MONTHLY*  
 **Zinbryta**<sup>®</sup>  
(daclizumab)  
150 mg Subcutaneous Injection

Please download the Full [Prescribing Information](#), including **Boxed Warning**, and [Medication Guide](#) on ZINBRYTA.com.



# Important Safety Information (cont'd)

ZINBRYTA can cause other serious side effects, including:

- **Allergic reactions or serious problems that may affect different parts of the body such as your liver, kidneys, heart or blood.** These can be very serious and can cause death. Call your healthcare provider right away if you have any of the following symptoms while using ZINBRYTA: fever, rash, swelling of the face, tongue, or throat, or trouble breathing.
- **Infections.** Some people who use ZINBRYTA may get an infection, such as an upper respiratory tract infection or a urinary tract infection. Some infections may be serious. Talk to your healthcare provider before you get vaccinations while using ZINBRYTA.
- **Depression and suicide.** Some people on ZINBRYTA may develop depression, depressed mood, or suicidal thoughts. Call your healthcare provider right away if you have any of the following symptoms while using ZINBRYTA: feel sad or have crying spells; are sleeping a lot more or a lot less than usual; feel hopeless or helpless; are more irritable, angry or aggressive than usual; have trouble paying attention; feel tired or sleepy all the time; have thoughts of hurting yourself or suicide.

**The most common side effects of ZINBRYTA include:** upper respiratory tract infection; flu, pain or swelling in your nose, throat, or mouth; bronchitis; abnormal liver function tests; dry, itchy, scaly, or inflamed skin (eczema); rash; depression and depressed mood; and swollen lymph glands. Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all the possible side effects of ZINBRYTA. To report side effects to FDA, please call 1-800-FDA-1088.

Please see Full [Prescribing Information](#) including **Boxed Warning** and [Medication Guide](#).

This information is not intended to replace discussions with your healthcare provider.

If you cannot afford your medications, Biogen and AbbVie may be able to help. Contact 1-800-456-2255 for more information.

Please download the Full [Prescribing Information](#), including **Boxed Warning**, and [Medication Guide](#) on ZINBRYTA.com.



abbvie

© 2017 Biogen. All rights reserved. 08/17 ZIN-US-0548 v2  
225 Binney Street, Cambridge, MA 02142 • 1.800.456.2255 • ZINBRYTA.com  
© 2017 AbbVie Inc. North Chicago, Illinois, U.S.A.



**Zinbryta**<sup>®</sup>  
(daclizumab)

150 mg Subcutaneous Injection

ONCE MONTHLY